The North America drug discovery market growth is expected to progress at a CAGR of 6.14% during the forecast period, 2022-2030, recording a revenue of $39860.74 million by 2030.

NORTH AMERICA DRUG DISCOVERY MARKET FORECAST 2022-2030

North America Drug Discovery Market by Drug Type (Small Molecule Drug, Biologic Drug) Market by Service (Chemical Services, Drug Metabolism and Pharmacokinetics Services, Biological Services, Other Pharmaceutical Services) Market by End-users (Pharmaceutical Companies, Contract Research Organizations, Research Institutes, Other End-users) Market by Technology (High Throughput Screening, Spectroscopy, Combinatorial Chemistry, Biochips, Pharmacogenomics and Pharmacogenetics, Bioinformatics, Metabolomics, Nanotechnology, Other Technologies) by Geography

Request free sample

The North America drug discovery market growth is expected to progress at a CAGR of 6.14% during the forecast period, 2022-2030, recording a revenue of $39860.74 million by 2030.

The market growth is attributed to technological advancements and their applications in drug discovery and development. Also, several market players are investing in R&D activities for optimal approaches to developing viable drug solutions and conducting projects in the pipeline.

North America Drug Discovery Market

To know more about this report, request a free sample copy

The North America drug discovery market growth assessment includes the analysis of Canada and the United States. In North America, the prevalence of chronic diseases, the aging population, and early technology adoption facilitate high market growth prospects. As per the CDC (Center for Disease Control and Prevention), chronic diseases account for around 90% of total healthcare expenditure in the US. Also, the rising investments in healthcare offer growth opportunities. In addition, technological advancements promote the safe and effective management of infusion therapies. These are administered for diseases like dehydration, cancer, congestive heart failure, immune deficiencies, rheumatoid arthritis, multiple sclerosis, etc.

Further, the government and CROs’ initiatives, awareness programs of drug discovery, and the presence of pharmaceutical companies benefit market growth. Moreover, the increased adoption of personalized medicine drives market growth in the US. Also, research studies are conducted in the country, thereby allowing manufacturers to develop novel drug delivery devices. Such aspects constitute the market prospects in the US.

The North America drug discovery market segmentation includes the evaluation of service, drug type, end-user, and technology. The market by service includes biological services, chemical services, drug metabolism and pharmacokinetics services, and other pharmaceutical services.

Drug metabolism and pharmacokinetics (DMPK) services are evaluated to gain more market share during the forecast period. In drug discovery, the role of pharmacokinetics (PK) is to supplement the optimization of the ADME properties (absorption, distribution, metabolism, and excretion) of lead compounds with the end goal of getting a clinical candidate that attains a concentration-time profile in the body adequate for safety profile and desired efficacy. DPMK studies are conducted throughout the drug development process, which aids in determining the pharmacological characteristics of a drug candidate.

Biological services are gaining traction in the drug discovery market. These include developing and manufacturing biologics or biological products. Several biologics are made from varied natural sources like animals, humans, microorganisms, etc. Also, some biologics are for treating medical conditions, while others are for disease prevention or diagnosis. Examples include human cells & tissues used for transplantation, blood & blood products for transfusion, vaccines, allergenic extracts, screening potential blood donors for infectious agents like HIV, cellular therapies, gene therapies, etc.

Some of the eminent firms in the North America drug discovery market include Merck & Co Inc, IQVIA Holdings Inc, Johnson & Johnson, Icon Plc, etc.

IQVIA offers clinical research, technology solutions, and advanced analytics services to the life sciences industry. The three operating services of the company include contract sales & medical solutions, research & development solutions, and technology & analytics solutions. It caters to consumer health companies, device & diagnostic companies, biotechnology companies, and pharmaceutical companies. It is headquartered in Durham, North Carolina, the United States.

The company’s Project Management and Clinical Monitoring solution and service enable efficient coordination and conduct of multi-site clinical trials. The service offerings include patient recruitment, feasibility & operational planning, clinical site monitoring, and protocol design.

Report Synopsis:

Report ScopeDetails
Market Forecast Years2022-2030
Base Year2021
Market Historical Years2018-2021
Forecast UnitsRevenue ($ Million)
Segments AnalyzedDrug Type, Service, End-User, and Technology
Countries AnalyzedUnited States and Canada
Companies Analyzed

Roche AG, Pfizer Inc, Bayer AG, Evotec SE, Agilent Technologies Inc, Icon Plc, AstraZeneca Plc, Charles River Laboratories International Inc, Novartis AG, Merck & Co Inc, Eli Lilly and Company, IQVIA Holdings Inc, Johnson & Johnson, and GlaxoSmithKline Plc

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • KEY DRIVERS
        • GROWING R&D FOR TACKLING SEVERAL DISEASES
        • TECHNOLOGICAL ADVANCEMENTS
      • KEY RESTRAINTS
        • EXTENSIVE TIME-CONSUMING PROCESS
        • HIGHLY REGULATED MARKET
        • PROJECT FEASIBILITY AND SUCCESS RATE
    1. KEY ANALYTICS
      • IMPACT OF COVID-19 ON DRUG DISCOVERY MARKET
      • KEY MARKET TRENDS
      • PORTER’S FIVE FORCES ANALYSIS
        • BUYERS POWER
        • SUPPLIERS POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • OPPORTUNITY MATRIX
      • DRUG DISCOVERY AND DEVELOPMENT PROCESS
        • DRUG DISCOVERY AND DEVELOPMENT
        • PRECLINICAL RESEARCH
        • CLINICAL RESEARCH
        • REGULATORY AUTHORITY REVIEW
        • POST MARKET SAFETY MONITORING
      • REGULATORY FRAMEWORK
    2. MARKET BY DRUG TYPE
      • SMALL MOLECULE DRUG
      • BIOLOGIC DRUG
    3. MARKET BY SERVICE
      • CHEMICAL SERVICES
      • DRUG METABOLISM AND PHARMACOKINETICS SERVICES
      • BIOLOGICAL SERVICES
      • OTHER PHARMACEUTICAL SERVICES
    4. MARKET BY END-USER
      • PHARMACEUTICAL COMPANIES
      • CONTRACT RESEARCH ORGANIZATIONS
      • RESEARCH INSTITUTES
      • OTHER END-USERS
    5. MARKET BY TECHNOLOGY
      • HIGH THROUGHPUT SCREENING
      • SPECTROSCOPY
      • COMBINATORIAL CHEMISTRY
      • BIOCHIPS
      • PHARMACOGENOMICS AND PHARMACOGENETICS
      • BIOINFORMATICS
      • METABOLOMICS
      • NANOTECHNOLOGY
      • OTHER TECHNOLOGIES
    6. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • UNITED STATES
          • CANADA
    1. COMPETITIVE LANDSCAPE
      • KEY STRATEGIC DEVELOPMENTS
        • MERGERS & ACQUISITIONS
        • PRODUCT LAUNCHES & DEVELOPMENTS
        • PARTNERSHIPS & AGREEMENTS
        • BUSINESS EXPANSIONS & DIVESTITURES
      • COMPANY PROFILES
        • AGILENT TECHNOLOGIES INC
        • ASTRAZENECA PLC
        • BAYER AG
        • CHARLES RIVER LABORATORIES INTERNATIONAL INC
        • ELI LILLY AND COMPANY
        • EVOTEC SE
        • GLAXOSMITHKLINE PLC
        • ICON PLC
        • IQVIA HOLDINGS INC
        • JOHNSON & JOHNSON
        • MERCK & CO INC
        • NOVARTIS AG
        • PFIZER INC
        • ROCHE AG

    LIST OF TABLES

    TABLE 1:  MARKET SNAPSHOT – NORTH AMERICA DRUG DISCOVERY

    TABLE 2:  REGULATORY FRAMEWORK

    TABLE 3:  NORTH AMERICA DRUG DISCOVERY MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 4:  NORTH AMERICA DRUG DISCOVERY MARKET, BY DRUG TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 5:  NORTH AMERICA DRUG DISCOVERY MARKET, BY SERVICE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 6:  NORTH AMERICA DRUG DISCOVERY MARKET, BY SERVICE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 7:  NORTH AMERICA DRUG DISCOVERY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 8:  NORTH AMERICA DRUG DISCOVERY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 9:  NORTH AMERICA DRUG DISCOVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 10:  NORTH AMERICA DRUG DISCOVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 11:  NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 12:  NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 13:  LEADING PLAYERS OPERATING IN NORTH AMERICA DRUG DISCOVERY MARKET

    TABLE 14:  LIST OF MERGERS & ACQUISITIONS

    TABLE 15:  LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

    TABLE 16:  LIST OF PARTNERSHIPS & AGREEMENTS

    TABLE 17:  LIST OF BUSINESS EXPANSIONS & DIVESTITURES                        

    LIST OF FIGURES

    FIGURE 1: KEY MARKET TRENDS

    FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

    FIGURE 3: OPPORTUNITY MATRIX

    FIGURE 4: DRUG DISCOVERY AND DEVELOPMENT PROCESS

    FIGURE 5: NORTH AMERICA DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2021

    FIGURE 6: NORTH AMERICA DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2022-2030 (IN $ MILLION)

    FIGURE 7: NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2022-2030 (IN $ MILLION)

    FIGURE 8: NORTH AMERICA DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY SERVICE, IN 2021

    FIGURE 9: NORTH AMERICA DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2022-2030 (IN $ MILLION)

    FIGURE 10: NORTH AMERICA DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS SERVICES, 2022-2030 (IN $ MILLION)

    FIGURE 11: NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2022-2030 (IN $ MILLION)

    FIGURE 12: NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2022-2030 (IN $ MILLION)

    FIGURE 13: NORTH AMERICA DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

    FIGURE 14: NORTH AMERICA DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)

    FIGURE 15: NORTH AMERICA DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS, 2022-2030 (IN $ MILLION)

    FIGURE 16: NORTH AMERICA DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)

    FIGURE 17: NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)

    FIGURE 18: NORTH AMERICA DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021

    FIGURE 19: NORTH AMERICA DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2022-2030 (IN $ MILLION)

    FIGURE 20: NORTH AMERICA DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2022-2030 (IN $ MILLION)

    FIGURE 21: NORTH AMERICA DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2022-2030 (IN $ MILLION)

    FIGURE 22: NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOCHIPS, 2022-2030 (IN $ MILLION)

    FIGURE 23: NORTH AMERICA DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2022-2030 (IN $ MILLION)

    FIGURE 24: NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2022-2030 (IN $ MILLION)

    FIGURE 25: NORTH AMERICA DRUG DISCOVERY MARKET, BY METABOLOMICS, 2022-2030 (IN $ MILLION)

    FIGURE 26: NORTH AMERICA DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2022-2030 (IN $ MILLION)

    FIGURE 27: NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)

    FIGURE 28: NORTH AMERICA DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

    FIGURE 29: UNITED STATES DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 30: CANADA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)       

    1. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • UNITED STATES
          • CANADA
    1. MARKET BY DRUG TYPE
      • SMALL MOLECULE DRUG
      • BIOLOGIC DRUG
    2. MARKET BY SERVICE
      • CHEMICAL SERVICES
      • DRUG METABOLISM AND PHARMACOKINETICS SERVICES
      • BIOLOGICAL SERVICES
      • OTHER PHARMACEUTICAL SERVICES
    3. MARKET BY END-USER
      • PHARMACEUTICAL COMPANIES
      • CONTRACT RESEARCH ORGANIZATIONS
      • RESEARCH INSTITUTES
      • OTHER END-USERS
    4. MARKET BY TECHNOLOGY
      • HIGH THROUGHPUT SCREENING
      • SPECTROSCOPY
      • COMBINATORIAL CHEMISTRY
      • BIOCHIPS
      • PHARMACOGENOMICS AND PHARMACOGENETICS
      • BIOINFORMATICS
      • METABOLOMICS
      • NANOTECHNOLOGY
      • OTHER TECHNOLOGIES

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type